Theodore L. Deweese

Theodore L. Deweese

Radiation Oncology

401 North Broadway Street, Weinberg BLDG, Floor-L1 (Lobby Level)
Weinberg BLDG, Floor-L1 (Lobby Level)
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 141 publications

Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.

Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.

Journal: The Lancet. Oncology

Published: January 06, 2026

Cell Type-Specific Effects of miR-21 Loss Attenuate Tumor Progression in MYC-Driven Prostate Cancer.

Cell Type-Specific Effects of miR-21 Loss Attenuate Tumor Progression in MYC-Driven Prostate Cancer.

Journal: bioRxiv : the preprint server for biology

Published: June 04, 2025

Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial.

Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 07, 2025

Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy.

Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy.

Journal: European urology oncology

Published: March 12, 2025

Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer.

Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: September 11, 2024

Long-term rectal patient-reported quality of life outcomes among patients treated with Pd-103 LDR prostate brachytherapy.

Long-term rectal patient-reported quality of life outcomes among patients treated with Pd-103 LDR prostate brachytherapy.

Journal: Brachytherapy

Published: June 27, 2024

Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer.

Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer.

Journal: European urology oncology

Published: February 17, 2024

Sexual function and dosimetric relationships to neighboring neurovascular substructures among patients treated definitively with Pd-103 LDR prostate brachytherapy.

Sexual function and dosimetric relationships to neighboring neurovascular substructures among patients treated definitively with Pd-103 LDR prostate brachytherapy.

Journal: Brachytherapy

Published: February 09, 2024

Developing the POTOMAC Model: A Novel Prediction Model to Study the Impact of Lymphopenia Kinetics on Survival Outcomes in Head and Neck Cancer Via an Ensemble Tree-Based Machine Learning Approach.

Developing the POTOMAC Model: A Novel Prediction Model to Study the Impact of Lymphopenia Kinetics on Survival Outcomes in Head and Neck Cancer Via an Ensemble Tree-Based Machine Learning Approach.

Journal: JCO clinical cancer informatics

Published: December 14, 2023

Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival After Stereotactic Ablative Radiation in Oligometastatic Prostate Cancer.

Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival After Stereotactic Ablative Radiation in Oligometastatic Prostate Cancer.

Journal: Advances in radiation oncology

Published: November 20, 2023

Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer.

Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer.

Journal: bioRxiv : the preprint server for biology

Published: October 31, 2023

Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer.

Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer.

Journal: Nature communications

Published: September 29, 2023

Showing 1-12 of 141

Last Updated: 09/26/2026